期刊文献+

艾塞那肽靶点治疗2型糖尿病患者的护理干预 被引量:1

Nursing of patients with type 2 diabetes mellitus using exenatide targets site treatment
原文传递
导出
摘要 目的探讨艾塞那肽在单用二甲双胍(MET)、磺酰脲类(su)或MET+SU联合治疗血糖控制欠佳的2型糖尿病患者中的疗效,寻找有效的护理对策。方法将24例患者随机分为对照组与艾塞那肽组各12例;艾塞那肽5gg2次/d先治疗4周,然后lOgg2次,d治疗12周。观察2组从基线到终点的糖化血红蛋白(HbAlc)、BMI、空腹血糖(FBG)、餐后2h血糖(P2hBG)指标的变化,及在护理干预前后2组的不良反应率。结果对照组患者HbAlc、BMI、FBG、P2hBG水平与治疗前无明显差异;艾塞那肽组治疗后与治疗前及治疗后的对照组相比上述指标的水平均显著下降,护理干预对应用艾塞那肽产生恶心、呕吐、腹泻、低血糖、头痛的不良反应均有显著效果。结论单用MET、SU或用MET+SU联合治疗控制效果欠佳的2型糖尿病患者,加用艾塞那肽靶点治疗可长期有效控制血糖,疗效卓越;通过护理干预可明显缓解不良反应对患者的影响。 Objective To explore exenatide in the treatment of mefformin(MET)alone, sulfonylurea (SU)alone or MET + SU combination therapy with poor glycemic control in type 2 diabetic pa-tients and to find effective nursing measures. Methods 24 patients were randomly divided into the con-trol group and the exenatide group with 12 patients in each group. In the exenatide group, exenatide 5μg twice a day for 4 weeks, then 10/.tg twice a day for 12 weeks. Changes of HbAle, body weight, BMI, FBG, P2hBG, and rate of adverse reaction were compared between two groups. Results Glycosylated hemoglobin (HbAlc), body weight, BMI, FBG, P'2hBG in the control group before and after treatment showed no significant difference, while the exenatide group showed better results compared with those before treatment and the control group. Nursing intervention played evident effect on reducing adverse effect such as nausea, vomiting, diarrhea, low blood sugar, headache. Conclusions For patients with type 2 diabetes, using MET, SU alone or MET + SU combination therapy showed poor results of blood sugar control, addition of exenatide therapy can effectively control blood sugar, nursing intervention can significantly alleviate the adverse effects of patients.
出处 《中国实用护理杂志》 北大核心 2012年第25期7-9,共3页 Chinese Journal of Practical Nursing
关键词 护理干预 艾塞那肽 靶点治疗 2型糖尿病 Nursing intervention Exenatide Target treatment Type 2 diabetes
  • 相关文献

参考文献7

  • 1Flint A, Raben A, Astrup A, et al. Determinants of appetite ratings:the role of age, gender, BMI, physical activity, smoking habits, and diet/weight eoneern.J Clin Invest, 1998,101(3 ) :515-520.
  • 2Nauek M,Stockmann F,Ebert R,et al. Redused ineertin effect in type 2 ( non-insulin-dependent ) diabete. Diabetologia, 1986,29:46-52.
  • 3Thorens B. Increased postprandial glycaemia,insulinemia,and lipi- demia after 10 weeks' sucrose- rich diet compared to an artificially sweetened diet:a randomised controlled trial. Diabetes Metab, 1995,21:311-318.
  • 4Baggio LL,Drucker DJ. Biology of incretins;GLP - 1 and GIP. Gas - troenterology,2007,132:2131-2157.
  • 5Nyberg J,Anderson MF,Meister B,et al. Integrated management of timber and deer. J Neurosci, 2005,25 : 1816 - 1825.
  • 6Nauck MA, Heimesaat MM, Orskov C,et al. Preserved inscetin activity of glucagon-like peptidel [7-36amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest, 1993,91:301- 307.
  • 7徐雯,田平.老年糖尿病病人胰岛素强化治疗中低血糖反应的观察与护理干预[J].护理研究(上旬版),2006,20(9):2299-2301. 被引量:28

二级参考文献8

共引文献27

同被引文献29

  • 1李显丽,李奕平,王晓苓.艾塞那肽治疗肥胖2型糖尿病的临床疗效观察[J].昆明医科大学学报,2012,33(4):125-127. 被引量:4
  • 2Brubaker PL, Drucker DJ. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and centralnervous system[J]. Endocrinology,2004,145 (6) :2653- 2659.
  • 3Parkes DG, Pittner R, Jodka C, et al. Insulinotropic actions of exendin4 and glucagon-like peptide-1 in vivo and in vitro [ J ]. Metabolism,2001,50(5) :583-589.
  • 4Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double- blind, placebo-controlled, parallel-group study [ J ]. Clin Ther, 2008 ,30 ( 8 ) : 1448-1460.
  • 5Norris SL, Lee N, Thakurta S, et al. Exenatide efficacy and safety: a systematic review [ J ]. Diabet Med, 2009 ,-26 ( 9 ) : 837- 846.
  • 6DeFronzo RA, Triplitt C, Qu Y, et al. Effects of exenatide plus rosiglitazone on 13-Cell function and insulin sensitivity in subjects with type 2 diabetes on mefformin [ J ]. Diabetes Care, 2010,33 (5) :951-957.
  • 7Traina AN, Lull ME, Hui AC, et al. Once-weekly exenatide as adjunct Ireatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapy [ J ]. Can J Diabetes,2014,38 (4) :269-272.
  • 8Fu Z, Kuang HY, Hao M, et al. Protection of exenatide for retinal ganglion cells with different glucose concentrations [ J ]. Peptides,2012,37 ( 1 ) :25-31.
  • 9Bunck MC, Diamant M, Com6r A, et al. One-Year treatment with exenatide improves β-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients : a randomized, controlled trial [ J ]. Diabetes Care, 2009,32 ( 5 ) : 762-768.
  • 10Diamant M, Gaal LV, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes ( DURATION-3 ) : an open-label randomised trial [ J ]. Lancet,2010,375 (9733) :2234-2243.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部